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Abstract: Cancer is one of the leading causes of deaths in the Western world. Approximately one-third of these deaths are 
preventable by lifestyle factors, including modiﬁ  cation of nutritional habits. Studies have demonstrated that adequate nutri-
tion with certain types of foods containing bioactive compounds might offer signiﬁ  cant protection against carcinogenesis. 
Soybeans contain a variety of phytochemicals with demonstrated anticancer activity, including isoﬂ  avones, protease 
inhibitors, and more recently lunasin, a novel cancer preventive seed peptide. Initially isolated from soybean, lunasin has 
also been reported in barley and wheat. The purpose of this review is to summarize the most recent evidence on the pos-
sible beneﬁ  ts of lunasin for cancer prevention.
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Introduction
Soybean (Glycine max) is a legume consumed worldwide, but most commonly in Asian countries 
where it is a staple used to prepare both fermented and non-fermented foods. Asians consume an aver-
age of 20 to 80 g of traditional soy foods daily, the most common of which are tofu, miso and tempeh. 
Recently, soybean foods have generated a lot of interest because of reported beneﬁ  cial effects on 
nutrition and health. It has been demonstrated that Asian populations consuming large amounts of 
soybean products have a lower risk of osteoporosis and some chronic diseases, most notably heart 
disease and cancer (McCue and Shetty, 2004). Epidemiological studies, animal experiments and in vitro 
studies have shown that soy products are associated with decreased risk for prostate (Jacobsen et al. 
1998; Lee et al. 2003), breast (Wu et al. 1998; Dai et al. 2002; Yamamoto et al. 2003) and endometrial 
cancers (Goodman et al. 1997).
Soybean contains a variety of phytochemicals with demonstrated anticancer activity, including pro-
tease inhibitors, inositol hexaphosphate (phytic acid), β-sitosterol, saponins, and isoﬂ  avones (Messina 76
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and Barnes, 1991). The most widely studied 
bioactive substances in soy are Bowman-Birk 
protease inhibitor (BBI) and the isoﬂ  avones. BBI 
is a serine protease inhibitor with a well-
characterized ability to inhibit trypsin and chymo-
trypsin. It has been shown to have anticarcinogenic 
effects on many different cell lines (Yavelow et al. 
1985; Billings and Habres, 1992; Kennedy, 
1998a, b; Zhang et al. 1999; Meyskens, 2001; 
Kennedy and Wan, 2002). Its capacity for prevent-
ing or suppressing carcinogenic processes has been 
also demonstrated in a wide variety of in vitro and 
in vivo animal model systems. In preclinical stud-
ies, BBI has been found to interfere effectively 
with the development of tumors induced by 
chemical carcinogens in the lung or gastrointesti-
nal tract of mice (Witschi and Kennedy, 1989; St 
Clair et al. 1990; Kennedy et al. 1996), the esoph-
agus and colon of rats (von Hofe et al. 1991; 
Kennedy et al. 2002) and the oral cavity of 
hamsters (Messadi et al. 1986) and with radiation-
induced lymphosarcoma in mice (Evans et al. 
1992). As a result of this evidence, BBI acquired 
the status of an “investigational new drug” from 
the FDA in 1992 and currently is being evaluated 
in large-scale human trials as an anticarcinogenic 
agent in the form of BBI concentrate (BBIC). 
The results of phase I and II clinical trials have 
shown that BBIC has a substantial positive clinical 
effect in patients with oral leukoplakia (Armstrong 
et al. 2000, 2003; Meyskens, 2001). At this time, 
a Phase IIb randomized, placebo-controlled clinical 
trial to determine the clinical effectiveness of BBIC 
is under way. BBI and BBIC evidently works 
by inhibiting proteases involved in initiation 
and promotion of carcinogenesis (Kennedy, 1994), 
but the biochemical and molecular bases for 
this mechanism of action need to be further 
elucidated.
The chemopreventive properties of soybean 
isoﬂ  avones, which are phytoestrogens, have been 
attributed to different biological activities, mainly 
to their long-term estrogenic effects and their 
antioxidant activity (McCue and Shetty, 2004). 
The administration of soy isoﬂ  avones in a soy 
protein matrix has raised the possibility that other 
proteins contribute to the observed preventive 
effects attributed to isoﬂ  avones mixtures (Pollard 
and Wolter, 2000). These observations gave spe-
cial importance to the discovery of the cancer 
preventive properties of the peptide lunasin dis-
covered in our laboratory.
Discovery of Lunasin
Lunasin is a unique 43-amino acid peptide which 
sequence is the following:
SKWQHQQDSCRKQKQGVNLTPC-
EKHIMEKIQG-RGD-DDDDDDDD
This peptide contains 8 Asp (D) residues in its 
carboxyl end (bold) preceded by a cell adhesion 
motif Arg-Gly-Asp (RGD) (italics) and a predicted 
helix (underlined) with structural homology to a 
conserved region of chromatin-binding proteins.
Lunasin was initially identiﬁ  ed in the soybean 
cotyledon when a cDNA encoding a post-
translationally processed 2S albumin (Gm2S-1) 
was cloned from mid-maturation soybean seed 
(Galvez et al. 1997). Gm2S-1 codes for a signal 
peptide, a small subunit (called lunasin, from the 
Tagalog word “lunas” for cure), a linker peptide, 
and a large subunit methionine-rich protein. Trans-
fection and expression of the lunasin gene inside 
mammalian cells result in mitotic arrests leading 
to cell death (Galvez and de Lumen, 1999). This 
antimitotic effect of this peptide has been attributed 
to the binding of its poly-D carboxyl end to regions 
of hypoacetylated chromatin, such as that found in 
kinetochores in centromeres. As a result, the 
kinetochore complex does not form properly, and 
the microtubules fail to attach to the centromeres, 
leading to mitotic arrest and eventually to cell death 
(Galvez and de Lumen, 1999).
Lunasin in Soybean 
and Other Seeds
A screening of the U.S. Department of Agriculture 
soybean germplasm collection showed that lunasin 
is present in the 144 analyzed soy genotypes in con-
centrations ranging from 6 to 7 mg of lunasin/g of 
protein (Gonzalez de Mejia et al. 2004). Jeong and 
co-workers have analyzed different Korean varieties 
of soybean which contain lunasin concentrations rang-
ing from 4.40 to 70.49 mg of lunasin/g of protein 
(Jeong et al. 2007a). These variations indicate that the 
levels of this peptide in soybeans can be genetically 
manipulated and suggest the possibility of selecting 
and breeding varieties of soy with higher lunasin 
content. It has been also demonstrated that large-scale 
processing of soy to produce different soy protein 
fractions inﬂ  uences lunasin concentration. This con-
centration varies from 12 to 44 mg lunasin/g of ﬂ  our 
in different U.S. commercially available soy proteins 
(Gonzalez de Mejia et al. 2004). The stages of seed 
development and sprouting also affect the concentration 77
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of lunasin in the soybean (Park et al. 2005). A notable 
increase of lunasin content occurs during seed matu-
ration. However, sprouting leads to a continuing 
decrease of lunasin with soaking time. Light and dark 
conditions do not seem to affect the content of this 
peptide (Park et al. 2005). These data are useful in the 
preparation of soy fractions enriched in lunasin as well 
as in recommendations of dietary intakes of lunasin.
In search of natural sources of lunasin besides 
soybean, the identiﬁ  cation, isolation and bioassay 
of lunasin from barley (Jeong et al. 2002) and wheat 
(Jeong et al. 2007b) have been reported. The 
amount of lunasin in the crude extracts of eight 
varieties of wheat ranges from 211 to 249 µg 
lunasin/g of seed. Such varying concentrations 
suggest the availability of lunasin in wheat food 
products to consumers (Jeong et al. 2002). Recently, 
lunasin has been also found in the Solanaceae fam-
ily (Jeong et al. 2007c), amaranth (Silva-Sanchez 
et al. 2008), and pepper (unpublished data).
Lunasin is a very heat stable peptide, surviving 
and retaining its activity even after 10 min of boil-
ing (de Lumen, 2005). In vitro digestibility studies 
have demonstrated that pure synthetic lunasin is 
digested by pancreatin (Galvez et al. 2001). How-
ever, animal studies using 
3H-labeled synthetic 
lunasin have shown that about the 35% of the oral 
dose is absorbed and ends up in the various tissues 
of mice and rats 6 hours after administration by 
gavage together with lunasin-enriched soy protein 
(de Lumen, 2005). Jeong and co-workers have 
studied in vivo digestibility of a lunasin-enriched 
soy (LES) in rats. These rats were fed LES for 4 
weeks and the liver and blood were analyzed for 
lunasin that was extracted in an intact and bioactive 
form (Jeong et al. 2007a). Similar results were 
found when rats were fed lunasin-enriched wheat 
(Jeong et al. 2007b). These observations suggest 
that in soy and wheat, naturally occurring protease 
inhibitors, such as BBIC and Kunitz Trypsin 
Inhibitor (KTI) protect lunasin from digestion in 
the gastrointestinal tract of humans and animals. 
The capacity of a compound to be absorbed after 
being orally administered and to reach the target 
tissues in a bioactive state is one of the most impor-
tant features of an ideal cancer preventive agent.
In Vitro and in Vivo Effects 
of Lunasin
Although its physiological signiﬁ  cance remains 
to be established, lunasin appears to be an ideal 
chemopreventive agent. Its chemopreventive 
properties both in vitro and in vivo have been 
demonstrated. In the absence of carcinogens, 
lunasin peptide added exogenously does not seem 
to affect cell morphology and proliferation but 
prevents transformation in the presence of car-
cinogens. At nanomolar concentrations, lunasin 
added exogenously to mouse ﬁ  broblasts cells 
C3H10T1/2 signiﬁ  cantly suppresses foci forma-
tion induced by the chemical carcinogens DMBA 
and MCA (Galvez et al. 2001). Colony formation 
is a measure of anchorage-independent cell 
growth, one of the characteristics of transformed 
cells. Lunasin suppresses colony formation in 
NIH3T3 cells, where it is 4-fold more effective, 
on a molar basis, than the BBI, a known cancer-
preventive agent from soy (Park et al. 2005).
Lunasin also prevents transformation of mam-
malian cells by viral oncogenes. It inhibits, in a 
dose-dependent manner, foci formation in C3H cells 
and NIH3T3 cells transfected with the oncogene 
E1A, known to induce cell proliferation by inactivat-
ing the tumor suppressor protein Rb (Lam et al. 
2003). Interestingly, lunasin is effective even when 
added up to 15 days after transfection with E1A 
gene, suggesting its efﬁ  cacy when applied even after 
the transformation event. Lunasin also suppresses 
colony formation induced by the ras-oncogene in 
MCF-7 cells stably transfected with an inducible 
form of the oncogene (Jeong et al. 2003).
The effect of Lunasin on cancer prevention has 
been also demonstrated using an in vivo mouse model. 
In this model, dermal application of lunasin at 250 
µg/week reduced skin tumor incidence in SENCAR 
mice treated with DMBA and TPA by approximately 
70% compared with the untreated control (Galvez 
et al. 2001). This treatment also reduced the tumor 
multiplicity (tumor/mouse), and delayed by two 
weeks the appearance of papilloma in the mice rela-
tive to the untreated control. Using a 
2H2O-labeling 
method to measure cell proliferation in vivo, it has 
been found that lunasin slows down epidermal cell 
proliferation in mouse skin in the absence and pres-
ence of DMBA (Hsieh et al. 2004).
Epigenetic Mechanism of Action
Chemical carcinogenesis and viral oncogenesis 
share common mechanism(s) involving changes 
in chromatin status that lunasin disrupts to suppress 
cancer formation. Lunasin peptide added exoge-
nously to mammalian cells treated with the histone 78
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deacetylases inhibitor sodium butyrate, internalizes 
into the cell and crosses the nuclear membrane, 
localizing in the nucleus. There, it binds speciﬁ  -
cally to deacetylated core histones H3 and H4, 
inhibiting their acetylation (Galvez et al. 2001; 
Jeong et al. 2002). Recently, the histone acetylation 
inhibitory properties of different soybean and 
wheat varieties have been demonstrated (Jeong 
et al. 2007a, b). As expected, the degree of inhibi-
tion correlated with lunasin concentration. Once 
extracted and puriﬁ  ed, lunasin shows properties of 
inhibiting core histone acetylation. It is effective 
at 10 nM, bringing about a 20% and 25% reduction 
in acetylated histones H3 and H4, respectively. At 
1000 nM, the acetylation reduction is 80% for H3 
histone and 75% for H4 histone, relative to the 
control (Jeong et al. 2007a). The afﬁ  nity of lunasin 
for hypoacetylated chromatin and its inhibitory 
effect on histone acetylation is relevant to the pro-
posed epigenetic mechanism of action using the 
E1A-Rb-HDAC model (Fig. 1, de Lumen, 2005). 
This model stipulates that lunasin selectively kills 
cells that are being transformed by disrupting the 
dynamics of histone acetylation-deacetylation 
when a transforming event occurs. The tumor sup-
pressor protein Rb functions by interacting with 
E2F promoter and recruiting histone deacetylase 
(HDAC) to keep the core histones in the deacety-
lated (repressed) state. The inactivation of Rb by 
the oncoprotein E1A dissociates the Rb-HDAC 
complex, exposing the deacetylated core histones 
for acetylation by histone acetyltransferases 
(HATs). When this event occurs, lunasin is trig-
gered into action and binds to the deacetylated core 
histones competing with the HATs and turning off 
transcription. We propose that the binding of luna-
sin to deacetylated core histones disrupts the 
dynamics of histone acetylation-deacetylation, 
which is perceived as abnormal by the cell and 
leads to apoptosis. This epigenetic mechanism 
DP E2F
E1A Rb
HAT LUNASIN
HDAC
HDAC
DP E2F
E1A Rb
Deacetylated Core Histone
TRANSCRIPTION ON
Acetylated Core 
Histone
S PHASE PROTEIN
HAT
TRANSCRIPTION OFF
Deacetylated Core 
Histone
LUNASIN
APOPTOSIS
Figure 1. E1A-Rb-HDAC model to explain the ability of Lunasin to suppress E1A-induced transformation. Top diagram: Rb controls G1/S 
transcription by interacting with E2F promoter and recruiting HDAC to keep the core histones in the deacetylated (repressed) state. In a cell 
being transformed, E1A inactivates Rb and dissociates Rb-HDAC complex, exposing the deacetylated core histones in the E2F promoter 
(middle diagram). Lunasin competes with histone acetyltransferase (HAT) in binding to the deacetylated core histones. Bottom diagram: 
HAT binds and acetylates core histones, turning on E2F cell cycle transcription factors, leads to cell proliferation. Lunasin binds, turns off 
the transcription, perceived as abnormal by cell, results in apoptosis.79
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suggests that lunasin can influence regulatory 
pathways involving chromatin modiﬁ  cations that 
may be fundamental to carcinogenic pathways in 
general, suggesting that lunasin could be effective 
against a number of cancers that involve chroma-
tin modiﬁ  cation. Interestingly, the tumor suppres-
sors Rb, p53 and pp32, function partly through 
chromatin modiﬁ  cation. We propose that when 
these tumor suppressors are inactivated lunasin 
takes over as a surrogate tumor suppressor and 
selectively kills cells that are being transformed.
The mechanism by which lunasin inhibits 
histone acetylation is not definitively known. 
Evidently, lunasin binds to deacetylated histone by 
ionic interaction with its negatively charged 
poly-D. Deletion of the coding region for poly-D 
in the lunasin cDNA nulliﬁ  es its antimitotic activ-
ity when transfected into mammalian cells (Galvez 
and de Lumen, 1999). The N-terminus of lunasin 
that includes the helical region may play a role in 
targeting lunasin to deacetylated histones (Galvez 
et al. 2001). Experiments are being carried out to 
elucidate the histone acetylation inhibitory mech-
anisms of lunasin.
Future Perspectives
Lunasin is a novel and promising chemopreventive 
peptide derived from soybean, wheat, barley, and 
other plant seeds. Its demonstrated cancer preven-
tive properties in vitro make lunasin a perfect 
candidate to exert an in vivo cancer-preventive 
activity. Further research is needed to demonstrate 
this activity. The preventive efﬁ  cacy of lunasin 
administered in the diet and other routes needs be 
tested against different types of cancer. In our 
laboratory, animal studies demonstrating this 
efﬁ  cacy against colon, prostate and breast cancer 
are currently being carried out. Moreover, the 
proposed epigenetic mechanism of action suggest-
ing that lunasin can be effective against cancers 
where chromatin modification is involved in 
carcinogenesis needs to be further elucidated 
through genomics and proteomics. There is still 
much to be learned about the effects of lunasin on 
cancer risks and this area of research holds 
considerable potential.
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